Age-dependent loss of MMP-3 in hutchinson-gilford progeria syndrome

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 66 A, Issue 11, 2011, Pages 1201-1207

  Harten, Ingrid A ^a,b   Zahr, Rima S ^c   Lemire, Joan M ^d   MacHan, Jason T ^e,f,g   Moses, Marsha A ^h   Doiron, Robert J ^h   Curatolo, Adam S ^h   Rothman, Frank G ⁱ   Wight, Thomas N ^a,b   Toole, Bryan P ^j   Gordon, Leslie B ^g,h  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d TUFTS UNIVERSITY   (United States)

^e Department of Biostatistics ^*  (United States)

^f RHODE ISLAND HOSPITAL   (United States)

^g BROWN UNIVERSITY   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ BROWN UNIVERSITY   (United States)

^j MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

HGPS; Lamin A; Matrix metalloproteinase; MMP; Progeria

Indexed keywords

STROMELYSIN;

AGING; ARTICLE; CELL CULTURE; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FIBROBLAST; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; PHYSIOLOGY; PROGERIA; REAL TIME POLYMERASE CHAIN REACTION; SKIN; WESTERN BLOTTING;

AGING; BLOTTING, WESTERN; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; MATRIX METALLOPROTEINASE 3; PROGERIA; REAL-TIME POLYMERASE CHAIN REACTION; SKIN;

EID: 80054914092     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glr137     Document Type: Article

References (50)

1. Merideth MA, Gordon LB, Clauss S, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008;358:592-604. (Pubitemid 351214286)
2. Olive M, Harten I, Mitchell R, et al. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol. 2010;30:2301-2309.
3. Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A. 2006;140:2603-2624. (Pubitemid 44865091)
4. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423:293-298. (Pubitemid 40852699)
5. Dechat T, Pfleghaar K, Sengupta K, et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008;22:832-853. (Pubitemid 351482836)
6. Csoka AB, English SB, Simkevich CP, et al. Genome-scale expression profiling of Hutchinson-Gilford progeria syndrome reveals widespread transcriptional misregulation leading to mesodermal/mesenchymal defects and accelerated atherosclerosis. Aging Cell. 2004;3:235-243. (Pubitemid 40246688)
7. Ly DH, Lockhart DJ, Lerner RA, Schultz PG. Mitotic misregulation and human aging. Science. 2000;287:2486-2492. (Pubitemid 30185444)
8. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006;11:529-543. (Pubitemid 43258162)
9. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1-31. (Pubitemid 40171256)
10. Chavey C, Mari B, Monthouel MN, et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem. 2003;278:11888-11896. (Pubitemid 36800160)
11. Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer. Head Neck. 2006;28:639-648. (Pubitemid 44025114)
12. Roy R, Louis G, Loughlin KR, et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008;14:6610-6617.
13. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004;23:101-117. (Pubitemid 38221598)
14. Okada Y, Nagase H, Harris ED Jr. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem. 1986;261:14245- 14255. (Pubitemid 17196334)
15. Beavan LA, Quentin-Hoffmann E, Schonherr E, Snigula F, Leroy JG, Kresse H. Deficient expression of decorin in infantile progeroid patients. J Biol Chem. 1993;268:9856-9862. (Pubitemid 23146049)
16. Colige A, Roujeau JC, De la Rocque F, Nusgens B, Lapiere CM. Abnormal gene expression in skin fibroblasts from a Hutchinson-Gilford patient. Lab Invest. 1991;64:799-806.
17. Giro M, Davidson JM. Familial co-segregation of the elastin phenotype in skin fibroblasts from Hutchinson-Gilford progeria. Mech Ageing Dev. 1993;70:163-136.
18. Lemire JM, Patis C, Gordon LB, Sandy JD, Toole BP, Weiss AS. Aggrecan expression is substantially and abnormally upregulated in Hutchinson-Gilford Progeria Syndrome dermal fibroblasts. Mech Ageing Dev. 2006;127:660-669.
19. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J. 1987;248:265-268. (Pubitemid 17161044)
20. Marquez-Aguirre A, Sandoval-Rodriguez A, Gonzalez-Cuevas J, et al. Adenoviral delivery of dominant-negative transforming growth factor beta type II receptor up-regulates transcriptional repressor SKI-like oncogene, decreases matrix metalloproteinase 2 in hepatic stellate cell and prevents liver fibrosis in rats. J Gene Med. 2009;11:207-219.
21. Dasu MR, Hawkins HK, Barrow RE, Xue H, Herndon DN. Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. J Pathol. 2004;202:476-485. (Pubitemid 38456166)
22. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA. 2005;102:15575-15580. (Pubitemid 41528098)
23. Nishijima C, Hayakawa I, Matsushita T, et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol. 2004;138:357-363. (Pubitemid 39472456)
24. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001;21:1440-1445. (Pubitemid 34219805)
25. Novak KB, Le HD, Christison-Lagay ER, et al. Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury. Pediatr Res. 2010;67:257-262.
26. Chan LW, Moses MA, Goley E, et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004;22:499-506. (Pubitemid 41079780)
27. Millis AJ, Hoyle M, McCue HM, Martini H. Differential expression of metalloproteinase and tissue inhibitor of metalloproteinase genes in aged human fibroblasts. Exp Cell Res. 1992;201:373-379.
28. Manicourt DH, Lefebvre V. An assay for matrix metalloproteinases and other proteases acting on proteoglycans, casein, or gelatin. Anal Biochem. 1993;215:171-179. (Pubitemid 23360902)
29. Cartwright MJ, Schlauch K, Lenburg ME, et al. Aging, depot origin, and preadipocyte gene expression. J Gerontol A Biol Sci Med Sci. 2010;65:242-251.
30. Eltarhouny SA, Elsawy WH, Radpour R, Hahn S, Holzgreve W, Zhong XY. Genes controlling spread of breast cancer to lung "gang of 4". Exp Oncol. 2008;30:91-95. (Pubitemid 351951382)
31. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol. 1997;6:199-213. (Pubitemid 27421661)
32. Scaffidi P, Misteli T. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med. 2005;11:440-445. (Pubitemid 40562336)
33. Kajanne R, Miettinen P, Mehlem A, et al. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol. 2007;212:489-497. (Pubitemid 47025639)
34. Yee J, Kuncio GS, Bhandari B, Shihab FS, Neilson EG. Identification of promoter activity and differential expression of transcripts encoding the murine stromelysin-1 gene in renal cells. Kidney Int. 1997;52:120-129. (Pubitemid 27321822)
35. Ivorra C, Kubicek M, Gonzalez JM, et al. A mechanism of AP-1 suppression through interaction of c-Fos with lamin A/C. Genes Dev. 2006;20:307-320. (Pubitemid 43200285)
36. Candelario J, Sudhakar S, Navarro S, Reddy S, Comai L. Perturbation of wild-type lamin A metabolism results in a progeroid phenotype. Aging Cell. 2008;7:355-367. (Pubitemid 351663904)
37. Garg A, Subramanyam L, Agarwal AK, et al. Atypical progeroid syndrome due to heterozygous missense LMNA mutations. J Clin Endocrinol Metab. 2009;94:4971-4983.
38. Lombardi F, Fasciglione GF, D'Apice MR, et al. Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome. Clin Genet. 2008;74:374-383.
39. Holliday DL, Hughes S, Shaw JA, Walker RA, Jones JL. Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res. 2007;9:R67.
40. King CR, Lemmer J, Campbell JR, Atkins AR. Osteosarcoma in a patient with Hutchinson-Gilford progeria. J Med Genet. 1978;15:481-484. (Pubitemid 9093452)
41. Bou-Gharios G, Osman J, Black C, Olsen I. Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis. Clin Chim Acta. 1994;231:69-78. (Pubitemid 24372393)
42. Bullard KM, Lund L, Mudgett JS, et al. Impaired wound contraction in stromelysin-1-deficient mice. Ann Surg. 1999;230:260-265. (Pubitemid 30191893)
43. Verstraeten VL, Ji JY, Cummings KS, Lee RT, Lammerding J. Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors. Aging Cell. 2008;7:383-393. (Pubitemid 351663907)
44. Terashima M, Akita H, Kanazawa K, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation. 1999;99:2717-2719. (Pubitemid 29250015)
45. Yoon S, Tromp G, Vongpunsawad S, Ronkainen A, Juvonen T, Kuivaniemi H. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun. 1999;265:563-568.
46. Gnasso A, Motti C, Irace C, et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol. 2000;20:1600-1605. (Pubitemid 30353894)
47. Rauramaa R, Vaisanen SB, Luong LA, et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2657-2662.
48. Agrotis A. The genetic basis for altered blood vessel function in disease: large artery stiffening. Vasc Health Risk Manag. 2005;1:333-344.
49. Kieran MW, Gordon L, Kleinman M. New approaches to progeria. Pediatrics. 2007;120:834-841. (Pubitemid 47549572)
50. Gordon LB, Harling-Berg CJ, Rothman FG. Highlights of the 2007 Progeria Research Foundation scientific workshop: progress in translational science. J Gerontol A Biol Sci Med Sci. 2008;63:777-787.